Get the Stockscreener App
21.45
2.01%
-0.44
After Hours:
21.45
Arrivent Biopharma Inc stock is traded at $21.45, with a volume of 185.69K.
It is down -2.01% in the last 24 hours and down -7.18% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$21.89
Open:
$21.84
24h Volume:
185.69K
Relative Volume:
0.58
Market Cap:
$733.86M
Revenue:
-
Net Income/Loss:
$-81.05M
P/E Ratio:
-8.177
EPS:
-2.6232
Net Cash Flow:
$-68.97M
1W Performance:
-5.59%
1M Performance:
-7.18%
6M Performance:
-21.43%
1Y Performance:
+4.58%
1-Day Range:
$20.81
$22.29
1-Week Range:
$20.81
$23.38
52-Week Range:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
21.45 | 791.15M | 0 | -81.05M | -68.97M | -2.6232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
What analysts say about ArriVent BioPharma Inc. stockExplosive returns - PrintWeekIndia
What risks could impact ArriVent BioPharma Inc. stock performanceTriple-digit returns - jammulinksnews.com
Is ArriVent BioPharma Inc. a good long term investmentPowerful market insights - Autocar Professional
ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug Data - MSN
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Rating of “Buy” from Analysts - Defense World
ArriVent BioPharma Inc. Stock Analysis and ForecastOverwhelming profit margins - jammulinksnews.com
ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
What drives ArriVent BioPharma Inc. stock priceAccelerated wealth expansion - jammulinksnews.com
What makes ArriVent BioPharma Inc. stock price move sharplyFree Stock Market Practical Discussion Forums - Newser
ArriVent BioPharma stock steady as Oppenheimer reiterates Outperform rating By Investing.com - Investing.com Canada
ArriVent Biopharma announces data from its FURVENT Phase 3 study - TipRanks
ArriVent expects topline data from lung cancer drug trial in early 2026 By Investing.com - Investing.com South Africa
ArriVent expects topline data from lung cancer drug trial in early 2026 - Investing.com
ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 - The Manila Times
New Strong Sell Stocks For July 21st - Barchart.com
New Strong Sell Stocks for July 21st - The Globe and Mail
Is ArriVent BioPharma Inc. stock a growth or value playDaily Price Surge List - Newser
P 500Low Risk Trade Timing Signals - Newser
60 Degrees Pharmaceuticals Secures $5 Million in Public Offering - AInvest
Why ArriVent BioPharma Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser
ArriVent BioPharma Conducts $75 Million Public Offering - Global Legal Chronicle
ArriVent BioPharma (NASDAQ:AVBP) Given a $33.00 Price Target by The Goldman Sachs Group Analysts - Defense World
The Goldman Sachs Group Reiterates “Buy” Rating for ArriVent BioPharma (NASDAQ:AVBP) - Defense World
How To Trade (AVBP) - news.stocktradersdaily.com
ArriVent BioPharma stock rating resumed at Buy by Goldman Sachs - Investing.com Canada
Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering - Mintz
ArriVent BioPharma stock maintains Buy rating at Clear Street despite competitor approval - Investing.com Canada
ArriVent BioPharma Announces $75 Million Public Offering - The Globe and Mail
Latham & Watkins Advises on ArriVent’s US$75 Million Common Stock Offering and Pre-Funded Warrants - Latham & Watkins LLP
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
ArriVent BioPharma Plans $75 Million Public Offering - MarketScreener
ArriVent BioPharma announces $75 million public offering By Investing.com - Investing.com UK
ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants - TradingView
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of “Buy” by Brokerages - Defense World
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.32%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):